Most people with myasthenia gravis live into their late 70s or beyond, though the disease does shorten life expectancy by a few years compared to the general population. With modern treatments, the outlook has improved dramatically from decades past, when myasthenic crises were frequently fatal. Today, the majority of patients achieve meaningful symptom control, and some reach full remission. But prognosis varies significantly depending on how the disease presents, how quickly it’s diagnosed, and how it responds to treatment.
Life Expectancy and Mortality Rates
A large study of 422 myasthenia gravis patients published in Frontiers in Neurology found that 14% of patients died within five years of symptom onset, and 21% died within ten years. The median age at death was 80 to 81 years, meaning most patients lived well into old age. However, compared to the general population, both men and women with MG died somewhat younger. Men with MG had an average age at death of 78.3 years versus 81.6 in the general population, while women showed a larger gap: 76.5 years versus 85.2.
These numbers represent averages across all severity levels and age groups. A younger person diagnosed with mild disease will have a very different trajectory than someone diagnosed in their 70s with severe generalized weakness. The mortality rate in the MG group was also substantially higher than in patients with other neurological or rheumatological conditions, reinforcing that MG carries real long-term health risks even with treatment.
How the Disease Typically Progresses
Myasthenia gravis often starts in the eyes, causing drooping eyelids or double vision. For some people, it stays there. About 30% to 40% of patients remain “ocular myasthenics,” with symptoms limited to the eye muscles. The remaining 50% to 70% progress to generalized MG, where weakness spreads to the limbs, neck, or muscles involved in swallowing and breathing. This progression typically happens within the first two years.
If you’ve had ocular symptoms for more than two years without generalization, the odds shift strongly in your favor. The risk of progression drops significantly after that window. This is one reason early monitoring matters so much: the first two years are the most volatile period, and catching generalization early allows for faster treatment adjustments.
Myasthenic Crisis
The most dangerous complication is myasthenic crisis, where the muscles responsible for breathing weaken to the point of respiratory failure. This requires emergency hospitalization and mechanical ventilation. The good news is that modern intensive care has reduced the mortality rate for crisis to less than 5% in the United States.
Certain factors raise the risk of experiencing a crisis: a history of previous crises, severe generalized disease, significant swallowing difficulty, the presence of a thymus tumor (thymoma), and a specific antibody subtype called MuSK. If you fall into any of these categories, your care team will typically monitor you more closely and may escalate treatment earlier to reduce the risk.
The Role of Thymectomy
Surgical removal of the thymus gland is a well-established treatment, particularly for patients with thymoma or those with generalized MG who are younger. The benefits, however, tend to unfold slowly. In a Colombian cohort study, half of patients reported symptom improvement by about one year after surgery, and 8% achieved complete stable remission by five years.
Timing matters. Patients who underwent thymectomy within 12 months of symptom onset experienced earlier and more robust remission at five years compared to those who waited longer. This suggests that earlier surgery, when appropriate, can meaningfully alter the long-term trajectory. That said, most patients still require medication after thymectomy, even if at lower doses.
Newer Treatments for Refractory Cases
For patients whose symptoms don’t respond adequately to standard immunosuppressive therapy, newer biologic medications have changed the outlook. Two classes of drugs now target specific parts of the immune system: complement inhibitors and antibody recycling blockers. Both reduce the immune attack on the nerve-muscle connection through different mechanisms.
One of the most meaningful effects has been reducing dependence on long-term steroids, which carry their own serious side effects. A study in Neurology found that patients starting complement inhibitor therapy reduced their annual steroid use by 36% within the first year. Antibody recycling blockers showed a 21% reduction, though that result was less statistically definitive. For patients who have spent years on high-dose steroids, these reductions translate to fewer bone, metabolic, and immune complications over time.
Quality of Life With MG
Living with myasthenia gravis affects daily functioning in ways that go beyond muscle weakness. In a study assessing quality of life across multiple domains, MG patients scored notably below the general population in physical functioning, energy levels, and general health perception. Physical limitations were the hardest hit area, with patients scoring an average of about 38 out of 100 on role limitations due to physical health (where 100 represents no limitations).
Disease severity was the strongest predictor. Patients classified as mild (limited eye symptoms or mild generalized weakness) reported significantly better physical and mental health scores than those with moderate or severe disease. But several non-medical factors also made a measurable difference. Regular moderate exercise, even twice a week, improved physical quality of life scores. Maintaining a healthy weight mattered: overweight and obese patients scored lower on both physical and mental health measures. Social support played a role too, with patients living with family reporting better mental health than those living alone. Employment, particularly in less physically demanding work, was associated with higher scores across the board.
Late-onset MG, diagnosed later in life, carried worse physical quality of life scores than early-onset disease. This likely reflects both the compounding effects of age-related health issues and potentially different immune mechanisms driving the disease in older patients.
Why Early Diagnosis Matters
Delayed diagnosis is a persistent problem with MG. Because early symptoms like fatigue, drooping eyelids, or intermittent weakness can mimic many other conditions, patients are frequently misdiagnosed before receiving the correct diagnosis. This delay increases disease severity and reduces quality of life by the time appropriate treatment begins. It also narrows the window for early thymectomy, which, as noted above, produces better outcomes when performed within the first year of symptoms. If you’re experiencing fluctuating muscle weakness that worsens with activity and improves with rest, pushing for a specialist evaluation with a neurologist can make a real difference in your long-term outcome.